Recent progress on novel immunotherapy in the treatment of chronic hepatitis B

doi:10.3877/cma.j.issn.1674-1358.2024.01.002

Abstract

Abstract:

Chronic hepatitis B (CHB) is still a public healthy problem all over the world, its consistent development can cause liver cirrhosis, hepatocellular carcinoma (HCC) and even death. At present, antiviral drugs can repress the replication of hepatitis B virus (HBV) DNA, reduce liver inflammation, reverse liver fibrosis and decreased the risk of cirrhosis and HCC. But it is still difficult to completely cure CHB, and the recurrence of virus is common after termination of treatment. Immunotherapy can break the immune tolerance and restore their immune response to HBV in CHB patients, and effective strategies of immunotherapy combined with direct antiviral drugs are expected to achieve the cure of CHB.

Key words: Chronic hepatitis B, Immunotherapy, Immunomodulator

Guanmei Chen, Xuan Zuo, Baolin Liao. Recent progress on novel immunotherapy in the treatment of chronic hepatitis B[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2024, 18(01): 7-10.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2024.01.002

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2024/V18/I01/7

References 35

[1]	Jeng W, Lok AS. What will it take to cure hepatitis B?[J]. Hepatol Commun,2023,7(4):e84.
[2]	Chang J, Block TM, Guo J. The innate immune response to hepatitis B virus infection: Implications for pathogenesis and therapy[J]. Antiviral Res,2012,96(3):405-413.
[3]	Li Q, Sun B, Zhuo Y, et al. Interferon and interferon-stimulated genes in HBV treatment[J]. Front Immunol,2022,13(1):1034968.
[4]	Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses[J]. Annu Rev Immunol,2014,32(10):513-545.
[5]	Yang G, Wan P, Zhang Y, et al. Innate Immunity, Inflammation, and Intervention in HBV Infection[J]. Viruses,2022,14(10):2275.
[6]	Han Q, Zhang C, Zhang J, et al. The role of innate immunity in HBV infection[J]. Semin Immunopathol,2013,35(1):23-38.
[7]	Du Y, Wu J, Liu J, et al. Toll-like receptor-mediated innate immunity orchestrates adaptive immune responses in HBV infection[J]. Front Immunol,2022,13:965018.
[8]	Duan T, Du Y, Xing C, et al. Toll-like receptor signaling and its role in cell-mediated immunity[J]. Front Immunol,2022,13:812774.
[9]	Yuen M, Balabanska R, Cottreel E, et al. TLR7 agonist RO7020531 versus placebo in healthy volunteers and patients with chronic hepatitis B virus infection: a randomised, observer-blind, placebo-controlled, phase 1 trial[J]. Lancet Infect Dis,2023,23(4):496-507.
[10]	Amin OE, Colbeck EJ, Daffis S, et al. Therapeutic potential of TLR8 agonist GS‐9688 (selgantolimod) in chronic hepatitis B: remodeling of antiviral and regulatory mediators[J]. Hepatology,2021,74(1):55-71.
[11]	Gane EJ, Kim HJ, Visvanathan K, et al. Safety, pharmacokinetics, and pharmacodynamics of the oral TLR8 agonist selgantolimod in chronic hepatitis B[J]. Hepatology,2021,74(4):1737-1749.
[12]	Reyes M, Lutz JD, Lau AH, et al. Safety, Pharmacokinetics and pharmacodynamics of selgantolimod, an oral Toll-like receptor 8 agonist: A phase Ⅰa study in healthy subjects[J]. Antivir Ther,2020,25(3):171-180.
[13]	Vajjhala PR, Ve T, Bentham A, et al. The molecular mechanisms of signaling by cooperative assembly formation in innate immunity pathways[J]. Mol Immunol,2017,86:23-37.
[14]	Nahavandi-Parizi P, Kariminik A, Montazeri M. Retinoic acid-inducible gene 1 (RIG-1) and IFN-β promoter stimulator-1 (IPS-1) significantly down-regulated in the severe coronavirus disease 2019 (COVID-19)[J]. Mol Biol Rep,2023,50(1):907-911.
[15]	Yuen M, Chen C, Liu C, et al. A phase 2, open-label, randomized, multiple-dose study evaluating Inarigivir in treatment-naïve patients with chronic hepatitis B[J]. Liver Int,2023,43(1):77-89.
[16]	Agarwal K, Afdhal N, Coffin C, et al. LBP04--Liver toxicity in the phase 2 catalyst 206 trial of Inarigivir 400 mg daily added to a nucleoside in HBV EAg negative patients[J]. J Hepatol,2020,73:S125.
[17]	Kuipery A, Gehring AJ, Isogawa M. Mechanisms of HBV immune evasion[J]. Antiviral Res,2020,179:104816.
[18]	Markham A. Envafolimab: First approval[J]. Drugs,2022,82(2):235-240.
[19]	Zhang F, Wei H, Wang X, et al. Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade[J]. Cell Discov,2017, 3(1):17004.
[20]	Gane E, Verdon DJ, Brooks AE, et al. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study[J]. J Hepatol,2019, 71(5):900-907.
[21]	Wu T, Stevens S, Liu C, et al. Discovery of oral PDL1 small molecule inhibitors specifically designed for the treatment of chronic hepatitis B[J]. J Hepatol,2022,77:S853.
[22]	Wang G, Qian J, Cui Y, et al. A phase Ⅱa trial of subcutaneously administered PD-L1 antibody ASC22 (Envafolimab) in patients with chronic hepatitis B[J]. 2021.Oral abstracts 91.
[23]	Meng Z, Chen Y, Lu M. Advances in Targeting the innate and adaptive immune systems to cure chronic hepatitis B virus infection[J]. Front Immunol,2020,10:3127.
[24]	Kruse RL, Shum T, Tashiro H, et al. HBsAg-redirected T cells exhibit antiviral activity in HBV-infected human liver chimeric mice[J]. Cytotherapy,2018,20(5):697-705.
[25]	Guo G, He W, Zhou Z, et al. PreS1-targeting chimeric antigen receptor T cells diminish HBV infection in liver humanized FRG mice[J]. Virology,2023,586:23-34.
[26]	Ebert G, Allison C, Preston S, et al. Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis[J]. PANS,2015,112(18): 803-5808.
[27]	Liu H, Hou J, Zhang X. Targeting cIAPs, a new option for functional cure of chronic hepatitis B infection?[J]. Virol Sin,2018,33(5):459-461.
[28]	Al Mahtab M, Akbar SMF, Yoshida O, et al. Antiviral response across genotypes after treatment of chronic hepatitis B patients with the therapeutic vaccine NASVAC or pegylated interferon[J]. Vaccines (Basel),2023,11(5):962.
[29]	Al Mahtab M, Akbar SMF, Aguilar JC, et al. Treatment of chronic hepatitis B naïve patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase Ⅲ clinical trial)[J]. PLoS One,2018,13(8):e201236.
[30]	Yoshida O, Akbar S, Imai Y, et al. Intranasal therapeutic vaccine containing HBsAg and HBcAg for patients with chronic hepatitis B; 18 months follow-up results of phase IIa clinical study[J]. Hepatol Res,2023,53(3):196-207.
[31]	Al-Mahtab M, Akbar SMF, Aguilar JC, et al. Safety profile, antiviral capacity, and liver protection of a nasal therapeutic vaccine in patients with chronic hepatitis B: Five-year-follow-up outcomes after the end of treatment[J]. Front Med,2023,10:1032531.
[32]	Wei L, Zhao T, Zhang J, et al. Efficacy and safety of a nanoparticle therapeutic vaccine in patients with chronic hepatitis B: A randomized clinical trial[J]. Hepatology,2022,75(1):182-195.
[33]	Su J, Brunner L, Ates Oz E, et al. Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models[J]. J Hepatol,2023,78(4):717-730.
[34]	Kosinska AD, Festag J, Mück-Häusl M, et al. Immunogenicity and antiviral response of therapeutic hepatitis B vaccination in a mouse model of HBeAg-negative, persistent HBV infection[J]. Vaccines,2021,9(8):841.
[35]	Bunse T, Kosinska AD, Michler T, et al. PD-L1 silencing in liver using siRNAs enhances efficacy of therapeutic vaccination for chronic hepatitis B[J]. Biomolecules,2022,12(3):470.

Please choose a citation manager

Content to export